Lomustine

洛莫司汀

Report date: 2022/03/09 15:35:12
NME

Base Information

Drug NameLomustine
Drug Alias Name氯乙环己亚硝脲Lomustinumlomustina洛莫司丁环已亚硝脲 +[11] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionDNA binders
TargetsDNA
Therapy Area/IndicationsCarcinoma, BronchogenicLung NeoplasmsBrain Neoplasms +[10] 
Global Approved IndicationsCarcinoma, BronchogenicBrain NeoplasmsStomach Neoplasms +[7] 
Approved Indications in ChinaCarcinoma, BronchogenicBrain NeoplasmsStomach Neoplasms +[6] 
Original Approved Country/TerritoryUnited States
Original Approved Date1976/08/04
Country/TerritoryCzechiaBelgiumUnited States +[13] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesCorden Pharma
China Registration ClassN/A

Develop Information

Active CompaniesSwiss Cancer InstituteApertus Pharmaceuticals LLCThe University Of California Davis +[6] 
Inactive CompaniesNational Cancer InstituteThe University Of Texas MD Anderson Cancer Center
Active IndicationsCarcinoma, BronchogenicBrain NeoplasmsStomach Neoplasms +[8] 
Inactive IndicationsLung NeoplasmsAstrocytoma

Other Information

ATC CodeL01AD02
Related LinksWikipediaDrugBankKEGG